OBJECTIVES: To assess the therapeutic efficacy of chloroquine (CQ) treatment against uncomplicated Plasmodium falciparum infections in a tribal population of central India (Madhya Pradesh) and to investigate the prevalence of mutant P. falciparum chloroquine-resistant transporter (pfcrt) gene in the parasite population. METHODS: Clinical and parasitological response was determined by in-vivo testing. For molecular testing, the parasite DNA was extracted from blood samples and used to amplify and sequence parts of the pfcrt (44-177 codons), MSP1 (block 2) and MSP2 (central repeat region) genes. RESULTS: Of 463 patients presenting fever, 137 tested positive for P. falciparum. They were treated with CQ. Of these, 58% participated in the study. Overall, treatment failure occurred in 53% of participants. Children under 5 years of age showed significantly more CQ resistance than adults. Mutant genotype S(72)V(73)M(74)N(75)T(76) was prevalent among both CQ responders (61.29%) and non-responders (66.7%). Interestingly, several patients from the CQ non-responder group (33.3%, n = 39) were harbouring parasite with wild type C(72)V(73)M(74)N(75)K(76) genotype of the pfcrt gene. Microsatellite sequences downstream of exon 2 varied widely among both wild type and mutant pfcrt haplotypes. CONCLUSION: The high rate of treatment failure in the present study clearly indicates the need to reassess the use of CQ as first-line antimalarial therapy in central India. This is supported by the presence of mutant pfcrt genotype among majority of the parasite population of the CQ non-responder group of patients. However, the presence of wild type amino acid at codon 76 of the pfcrt gene among several patients with CQ non-responders requires further investigations.
OBJECTIVES: To assess the therapeutic efficacy of chloroquine (CQ) treatment against uncomplicated Plasmodium falciparum infections in a tribal population of central India (Madhya Pradesh) and to investigate the prevalence of mutant P. falciparumchloroquine-resistant transporter (pfcrt) gene in the parasite population. METHODS: Clinical and parasitological response was determined by in-vivo testing. For molecular testing, the parasite DNA was extracted from blood samples and used to amplify and sequence parts of the pfcrt (44-177 codons), MSP1 (block 2) and MSP2 (central repeat region) genes. RESULTS: Of 463 patients presenting fever, 137 tested positive for P. falciparum. They were treated with CQ. Of these, 58% participated in the study. Overall, treatment failure occurred in 53% of participants. Children under 5 years of age showed significantly more CQ resistance than adults. Mutant genotype S(72)V(73)M(74)N(75)T(76) was prevalent among both CQ responders (61.29%) and non-responders (66.7%). Interestingly, several patients from the CQ non-responder group (33.3%, n = 39) were harbouring parasite with wild type C(72)V(73)M(74)N(75)K(76) genotype of the pfcrt gene. Microsatellite sequences downstream of exon 2 varied widely among both wild type and mutant pfcrt haplotypes. CONCLUSION: The high rate of treatment failure in the present study clearly indicates the need to reassess the use of CQ as first-line antimalarial therapy in central India. This is supported by the presence of mutant pfcrt genotype among majority of the parasite population of the CQ non-responder group of patients. However, the presence of wild type amino acid at codon 76 of the pfcrt gene among several patients with CQ non-responders requires further investigations.
Authors: Sri Krishna; Sweta Mishra; Prakash Tiwari; Anup K Vishwakarma; Sushrikanta Khandai; Suyesh Shrivastava; Anil K Verma; Shashikant Tiwari; Hari Barman; Surendra Jhariya; Pradeep Tiwari; Anup S Tidgam; Brij M Varun; Sunil Singh; Naresh Yerane; Chintaman R Tembhurne; Prem L Mandavi; Shyam S Tekam; Manas Malik; Kali P Behera; Himanshu Jayswar; Khemraj Sonwani; Mukund S Diggikar; Madan M Pradhan; Sher S Khasotiya; Avdhesh Kumar; Neeraj Dhingra; Maria Dorina G Bustos; Eva-Maria Christophel; Pascal Ringwald; Roop Kumari; Man M Shukla; Neeru Singh; Aparup Das; Praveen K Bharti Journal: Malar J Date: 2021-05-21 Impact factor: 2.979
Authors: Sweta Mishra; Praveen K Bharti; Man M Shukla; Nazia A Ali; Sher S Kashyotia; Avdhesh Kumar; Akshay C Dhariwal; Neeru Singh Journal: Pathog Glob Health Date: 2017-05-26 Impact factor: 2.894
Authors: Amidou Diarra; Issa Nebie; Alfred Tiono; Issiaka Soulama; Alphonse Ouedraogo; Amadou Konate; Michael Theisen; Daniel Dodoo; Alfred Traore; Sodiomon B Sirima Journal: Malar J Date: 2012-03-22 Impact factor: 2.979
Authors: Kalyan B Saha; Ravendra K Sharma; Rajdeep Mishra; Arvind Verma; B K Tiwari; Neeru Singh Journal: Indian J Med Res Date: 2015-05 Impact factor: 2.375